Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | 1 | 1 | — | — | — | 1 |
Drug common name | TAVOKINOGENE TELSEPLASMID |
INN | tavokinogene telseplasmid |
Description | Tavokinogene telseplasmid is a gene pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Gene |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4298206 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | MF4P7VQ2K8 (ChemIDplus, GSRS) |